Literature DB >> 17287139

S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden.

Andrea Carmine Belin1, Marie Westerlund, Olle Bergman, Hans Nissbrandt, Charlotta Lind, Olof Sydow, Dagmar Galter.   

Abstract

Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is a neuron-specific enzyme that removes ubiquitin from the C-terminal end of substrates and a component of the ubiquitin-proteasome system. A protective effect of a UCH-L1 variant, S18Y, was suggested since the common variant was found to be inversely associated with sporadic Parkinson's disease (PD). We investigated the association of S18Y in our Swedish PD material. The tyrosine variant was significantly inversely associated with PD (P=0.049) and with a low age of onset (50 years) (P=0.017) in the case-control material, supporting the hypothesis of a protective function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287139     DOI: 10.1016/j.parkreldis.2006.12.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system.

Authors:  Jeanne E McKeon; Di Sha; Lian Li; Lih-Shen Chin
Journal:  Cell Mol Life Sci       Date:  2014-11-18       Impact factor: 9.261

Review 2.  Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age.

Authors:  Ying Liu; Yan-Yan Chen; Hui Liu; Ci-Jiang Yao; Xiao-Xia Zhu; Dao-Jun Chen; Jin Yang; You-Jin Lu; Ji-Yu Cao
Journal:  Neurol Sci       Date:  2014-11-06       Impact factor: 3.307

3.  Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease.

Authors:  Madeleine Zetterberg; Annica Sjölander; Malin von Otter; Mona Seibt Palmér; Sara Landgren; Lennart Minthon; Anders Wallin; Niels Andreasen; Kaj Blennow; Henrik Zetterberg
Journal:  Mol Neurodegener       Date:  2010-03-19       Impact factor: 14.195

Review 4.  Parkinson's disease: Exit toxins, enter genetics.

Authors:  Marie Westerlund; Barry Hoffer; Lars Olson
Journal:  Prog Neurobiol       Date:  2009-11-17       Impact factor: 11.685

5.  Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.

Authors:  Carolyn M Hutter; Ali Samii; Stewart A Factor; John G Nutt; Donald S Higgins; Thomas D Bird; Alida Griffith; John W Roberts; Berta C Leis; Jennifer S Montimurro; Denise M Kay; Karen L Edwards; Haydeh Payami; Cyrus P Zabetian
Journal:  Eur J Neurol       Date:  2007-12-18       Impact factor: 6.089

6.  Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts.

Authors:  Thiemo Rudolph; Annica Sjölander; Mona Seibt Palmér; Lennart Minthon; Anders Wallin; Niels Andreasen; Gunnar Tasa; Erkki Juronen; Kaj Blennow; Henrik Zetterberg; Madeleine Zetterberg
Journal:  Ophthalmic Genet       Date:  2011-01-26       Impact factor: 1.803

Review 7.  Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.

Authors:  Margaret Ragland; Carolyn Hutter; Cyrus Zabetian; Karen Edwards
Journal:  Am J Epidemiol       Date:  2009-10-28       Impact factor: 4.897

8.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Authors:  Valerie Cullen; Maria Lindfors; Juliana Ng; Anders Paetau; Erika Swinton; Piotr Kolodziej; Heather Boston; Paul Saftig; John Woulfe; Mel B Feany; Liisa Myllykangas; Michael G Schlossmacher; Jaana Tyynelä
Journal:  Mol Brain       Date:  2009-02-09       Impact factor: 4.041

9.  UCHL1 S18Y variant is a risk factor for Parkinson's disease in Japan.

Authors:  Yoshihiro Miyake; Keiko Tanaka; Wakaba Fukushima; Chikako Kiyohara; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Hiroyuki Shimada; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  BMC Neurol       Date:  2012-07-28       Impact factor: 2.474

Review 10.  Molecular pathology of Lewy body diseases.

Authors:  Katrin Beyer; Montserrat Domingo-Sàbat; Aurelio Ariza
Journal:  Int J Mol Sci       Date:  2009-02-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.